论文部分内容阅读
目的：口服髓鞘碱性蛋白（ｍｙｅｌｉｎｂａｓｉｃｐｒｏｔｅｉｎ，ＭＢＰ）与Ｔ细胞疫苗接种（Ｔｃｅｌｖａｃｃｉｎａｔｉｏｎ，ＴＣＶ）联合应用诱导免疫耐受，以提高特异性的免疫疗法对实验性自身免疫性脑脊髓膜炎（ｅｘｐｅｒｉｍｅｎｔａｌａｕｔｏｉｍｍｕｎｅｅｎｃｅｐｈａｌｏｍｙｅｌｉｔｉｓ，ＥＡＥ）的防治效果。方法：从ｇｐＳＣＨ／ＣＦＡ诱发ＥＡＥ的ＤＡ大鼠体内取淋巴细胞，体外再以ＭＢＰ刺激，并用ｒＩＬ２促进增殖，反复数个循环，可获得ＭＢＰ特异的Ｔ淋巴细胞系。将此Ｔ细胞系经照射（１５Ｇｙ）灭活处理后，静脉接种至同基因正常ＤＡ大鼠体内，同时给此ＤＡ大鼠多次口服ＭＢＰ诱导耐受，最后以脊髓匀浆／完全福氏佐剂（ＳＣＨ／ＣＦＡ）攻击经上述处理的大鼠，以观察其ＥＡＥ的发病情况。结果：单独口服ＭＢＰ诱导耐受及单独ＴＣＶ处理的ＤＡ大鼠对随后诱发的ＥＡＥ的抑制率分别为６７％和５０％，而将二者联合应用，则抑制率可达８０％。结论：口服ＭＢＰ与ＭＢＰ特异的Ｔ细胞疫苗接种联合应用，可获得更深程度的耐受效果，多种手段联合应用可能成为临床今后通过诱导耐受防治自身免疫病的新策略。
OBJECTIVE: To induce immune tolerance by combining oral myelin basic protein (MBP) with T cell vaccination (TCV) in order to improve the efficacy of specific immunotherapy on experimental autoimmune encephalomyelitis EAE) control effect. METHODS: Lymphocytes were isolated from gpSCH / CFA-induced DA rats and stimulated with MBP in vitro. The cells were stimulated with rIL-2 for several cycles to obtain MBP-specific T lymphocyte lines. The T cell line was irradiated (15Gy) inactivated after intravenous inoculation of normal DA rats in vivo, while giving this DA multiple oral MBP-induced tolerance, and finally to spinal cord homogenate / Complete Freund’s Adjuvant (SCH / CFA) challenge the rats treated as described above to observe the incidence of their EAE. Results: The inhibition rate of EAE induced by MBP-induced tolerance and TCV alone was 67% and 50%, respectively. However, the combination of the two agents inhibited the growth of EAE to 80%. Conclusion: The combined application of oral MBP and MBP-specific T cell vaccine can achieve a deeper tolerance effect. The combination of various means may be a new strategy for the prevention and treatment of autoimmune diseases in the future through induction of tolerance.